Key result
The constructed integrated database contains 9,890 hERG inhibitors and 281,329 inactive compounds, providing more than twice as many chemical scaffolds for hERG inhibitors than individual databases.
An integrated database of hERG inhibitors was constructed, providing a comprehensive resource with expanded chemical scaffold diversity to aid in predicting QT prolongation risk during drug discovery.
Greater scaffold diversity in integrated hERG datasets may enhance ML generalizability; leaves open clinical utility for QT risk prediction.
The inhibition of the hERG potassium channel is closely related to the prolonged QT interval, and thus assessing this risk could greatly facilitate the development of therapeutic compounds and the withdrawal of hazardous marketed drugs. The recent increase in SAR information about hERG inhibitors in public databases has led to many successful applications of machine learning techniques to predict hERG inhibition. However, most of these reports constructed their prediction models based on only one SAR database because the differences in the data format and ontology hindered the integration of the databases. In this study, we curated the hERG-related data in ChEMBL, PubChem, GOSTAR, and hERGCentral, and integrated them into the largest database about hERG inhibition by small molecules. Assessment of structural diversity using Murcko frameworks revealed that the integrated database contains more than twice as many chemical scaffolds for hERG inhibitors than any of the individual databases, and covers 18.2% of the Murcko framework-based chemical space occupied by the compounds in ChEMBL. The database provides the most comprehensive information about hERG inhibitors and will be useful to design safer compounds for drug discovery. The database is freely available at http://drugdesign.riken.jp/hERGdb/.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2018) studied hERG inhibition (drug-induced QT prolongation risk) (n=291,219). Integrated hERG database was evaluated on Construction of an integrated database and assessment of structural diversity. The constructed integrated database contains 9,890 hERG inhibitors and 281,329 inactive compounds, providing more than twice as many chemical scaffolds for hERG inhibitors than individual databases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: